| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 2,269 | 2,291 | 2,286 | 2,300 | 2,310 | 2,232 | 2,360 | 2,266 | 2,479 | 2,127 | 3,165 | 3,206 | 3,197 | 2,870 | 2,875 | 3,547 | 3,658 | 3,429 | 3,271 | 3,555 | 3,672 | 3,462 | 3,663 | 3,645 | 3,551 | 3,971 | 6,106 | 3,590 | 3,821 | 3,989 | 3,993 | 4,199 | 4,890 | 5,089 | 4,313 | 4,403 | 5,526 | 6,110 | 5,182 | 5,181 | 6,371 |
| Expenses | 1,792 | 1,807 | 1,740 | 1,768 | 1,784 | 1,763 | 1,841 | 1,907 | 2,004 | 1,909 | 2,365 | 2,404 | 2,399 | 2,249 | 2,273 | 2,738 | 2,932 | 2,864 | 3,009 | 2,947 | 3,013 | 2,724 | 2,977 | 2,867 | 2,916 | 3,092 | 2,860 | 2,895 | 3,103 | 3,251 | 3,319 | 3,301 | 4,359 | 3,650 | 3,224 | 3,403 | 3,903 | 4,124 | 3,776 | 3,882 | 4,622 |
| EBITDA | 477 | 484 | 546 | 532 | 526 | 468 | 519 | 359 | 476 | 218 | 800 | 802 | 798 | 621 | 601 | 809 | 726 | 565 | 262 | 608 | 658 | 738 | 686 | 779 | 635 | 879 | 3,246 | 695 | 718 | 738 | 673 | 898 | 532 | 1,439 | 1,089 | 1,000 | 1,623 | 1,986 | 1,407 | 1,299 | 1,749 |
| Operating Profit % | 20 % | 20 % | 23 % | 22 % | 21 % | 20 % | 21 % | 15 % | 17 % | 9 % | 25 % | 24 % | 24 % | 19 % | 20 % | 22 % | 19 % | 16 % | 7 % | 17 % | 17 % | 20 % | 17 % | 20 % | 19 % | 21 % | 22 % | 18 % | 17 % | 17 % | 16 % | 21 % | 10 % | 28 % | 24 % | 22 % | 27 % | 32 % | 26 % | 24 % | 27 % |
| Depreciation | 76 | 69 | 73 | 74 | 76 | 84 | 86 | 90 | 114 | 122 | 126 | 147 | 144 | 142 | 148 | 154 | 156 | 172 | 172 | 174 | 179 | 173 | 175 | 176 | 175 | 183 | 177 | 177 | 185 | 181 | 182 | 182 | 179 | 180 | 184 | 195 | 205 | 215 | 234 | 229 | 238 |
| Interest | 16 | 12 | 13 | 12 | 16 | 14 | 15 | 7 | 10 | 22 | 41 | 13 | 15 | 35 | 36 | 46 | 77 | 89 | 90 | 81 | 83 | 68 | 45 | 27 | 23 | 27 | 30 | 31 | 39 | 34 | 35 | 33 | 28 | 18 | 9 | 20 | 35 | 32 | 25 | 32 | 77 |
| Profit Before Tax | 426 | 519 | 545 | 537 | 498 | 441 | 435 | 324 | 412 | 154 | 712 | 722 | 724 | 570 | 535 | 672 | 606 | 394 | 122 | 457 | 522 | 588 | 524 | 617 | 526 | 777 | 3,135 | 598 | 558 | 673 | 648 | 781 | 484 | 1,328 | 1,006 | 947 | 1,550 | 1,900 | 1,271 | 1,184 | 1,672 |
| Tax | 69 | 51 | 60 | 97 | -74 | 36 | 46 | -6 | 20 | 9 | 200 | 168 | 125 | 102 | 107 | 150 | 124 | 69 | 28 | 86 | 108 | 102 | 89 | 89 | -210 | 135 | 123 | 87 | 105 | 96 | 122 | 149 | 125 | 195 | 203 | 157 | 304 | 417 | 351 | 158 | 428 |
| Net Profit | 357 | 468 | 485 | 440 | 572 | 405 | 389 | 331 | 393 | 145 | 513 | 553 | 599 | 467 | 428 | 522 | 482 | 325 | 94 | 371 | 414 | 487 | 435 | 528 | 735 | 643 | 3,012 | 511 | 453 | 576 | 526 | 631 | 358 | 1,134 | 803 | 790 | 1,246 | 1,483 | 920 | 1,026 | 1,244 |
| EPS in ₹ | 17.11 | 22.47 | 6.46 | 4.21 | 5.59 | 3.89 | 3.71 | 3.16 | 3.77 | 1.35 | 4.92 | 5.31 | 5.77 | 4.50 | 4.08 | 4.99 | 4.40 | 2.97 | 1.05 | 3.65 | 3.83 | 4.43 | 4.62 | 5.15 | 6.64 | 5.74 | 29.32 | 4.89 | 3.88 | 5.06 | 5.15 | 6.15 | 2.93 | 10.74 | 7.91 | 7.80 | 11.69 | 14.11 | 9.06 | 10.17 | 11.64 |
Zydus Life Science
908.60
+5.15
(0.57%)
Market Cap
91,426.40 Cr
EPS
38.14
PE Ratio
19.56
Dividend Yield
1.21 %
Industry
Healthcare52 Week High
1,324.30
52 Week Low
795.00
PB Ratio
3.81
Debt to Equity
0.05
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from28 analysts
Company News
View All News
Zydus Lifesciences: FDA Approves Generic Severe Acne Treatment1 day ago
Zydus Lifesciences received FDA approval for isotretinoin capsules in six dosage strengths, a generic version of Absorica for severe nodular acne. The US market for this drug is estimated at $115.4 million annually. Zydus now has 427 final FDA approvals.
Zydus Lifesciences Receives USFDA Approval for Isotretinoin Capsules1 day ago
Zydus Lifesciences has received final approval from the U.S. Food and Drug Administration (USFDA) for Isotretinoin Capsules USP in various strengths: 10 mg, 20 mg, 25 mg, 30 mg, 35 mg, and 40 mg. The approved drug had annual sales of $115.4 million in the United States, according to IQVIA MAT March 2025 data.
Zydus Lifesciences: Q4 Revenue and EBITDA Surge, U.S. Generic Growth Surprises4 days ago
Zydus Lifesciences reported Q4 FY25 revenue of Rs 65,279 million, up 18.0% YoY. EBITDA increased 30.4% YoY to Rs 21,255 million, with margin expanding to 32.6%. PAT declined 1% YoY to Rs 11,709 million. U.S. generic growth exceeded expectations.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,683.60 | #1 4,03,952.00 | 35.21 | #1 49,887.20 | 12.06 | #1 9,648 | -18.99 | 40.74 | |
6,483.00 | 1,72,103.30 | 78.53 | 8,184.00 | 0.89 | 1,600 | 23.05 | 63.44 | |
1,484.20 | 1,19,866.20 | 22.74 | 26,520.70 | 14.17 | 4,155 | 30.28 | 47.86 | |
3,174.70 | 1,07,446.30 | 55.70 | 10,785.70 | 11.59 | 1,656 | 10.91 | 43.82 | |
1,230.10 | 1,02,646.40 | #1 18.15 | 28,905.40 | 12.36 | 5,578 | 21.14 | 62.40 | |
2,432.40 | 1,00,355.60 | 50.56 | 10,615.60 | 19.57 | 1,942 | -10.91 | 44.37 | |
908.60 | #7 91,426.40 | #2 19.56 | #6 19,831.50 | #5 13.82 | #4 3,831 | #7 -0.19 | 56.78 | |
1,978.90 | 90,344.90 | 27.54 | 20,141.50 | #1 19.94 | 1,936 | #1 112.49 | 44.10 | |
1,197.10 | 69,527.80 | 19.71 | 29,559.20 | 17.55 | 3,169 | -10.04 | 50.83 | |
30,795.00 | 65,437.20 | 46.30 | 6,097.20 | 10.80 | 1,201 | 27.83 | 54.40 |
Forecast
Actual
Growth Rate
Revenue Growth
13.82 %
Net Income Growth
91.39 %
Cash Flow Change
20.05 %
ROE
70.50 %
ROCE
52.01 %
EBITDA Margin (Avg.)
23.08 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 9,047 | 10,551 | 15,221 | 18,065 | 23,483 | 23,687 | 23,885 | 27,795 | 25,756 | 29,281 |
| Fixed Assets | 3,352 | 3,748 | 5,755 | 6,483 | 12,164 | 12,231 | 12,133 | 12,189 | 11,521 | 12,369 |
| Current Assets | 4,227 | 4,280 | 6,022 | 8,230 | 8,498 | 8,715 | 8,716 | 12,095 | 10,008 | 11,420 |
| Capital Work in Progress | 798 | 951 | 1,543 | 1,527 | 837 | 742 | 783 | 726 | 1,201 | 2,423 |
| Investments | 121 | 416 | 435 | 746 | 674 | 765 | 830 | 3,288 | 1,547 | 1,221 |
| Other Assets | 4,776 | 5,436 | 7,488 | 9,310 | 9,809 | 9,950 | 10,139 | 11,593 | 11,488 | 13,269 |
| Total Liabilities | 9,047 | 10,551 | 15,221 | 18,065 | 23,483 | 23,687 | 23,885 | 27,795 | 25,756 | 29,281 |
| Current Liabilities | 3,285 | 3,461 | 5,306 | 6,083 | 7,343 | 8,269 | 7,861 | 7,827 | 5,527 | 5,340 |
| Non Current Liabilities | 1,342 | 1,255 | 2,799 | 3,047 | 4,461 | 3,707 | 1,094 | 915 | 541 | 1,840 |
| Total Equity | 4,421 | 5,835 | 7,116 | 8,936 | 11,679 | 11,710 | 14,930 | 19,054 | 19,688 | 22,102 |
| Reserve & Surplus | 4,149 | 5,597 | 6,858 | 8,642 | 10,284 | 10,273 | 12,890 | 16,897 | 17,415 | 19,729 |
| Share Capital | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 101 | 101 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 178 | 99 | 756 | -3 | -811 | 399 | -91 | 219 | -170 | -75 |
| Investing Activities | -465 | -860 | -2,872 | -974 | -3,977 | -1,004 | -837 | -1,018 | 1,542 | -1,492 |
| Operating Activities | 994 | 1,894 | 1,312 | 919 | 1,282 | 2,932 | 3,294 | 2,105 | 2,689 | 3,228 |
| Financing Activities | -351 | -935 | 2,316 | 52 | 1,885 | -1,528 | -2,548 | -868 | -4,400 | -1,810 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 74.88 % | 74.88 % | 74.88 % | 74.88 % | 74.88 % | 74.88 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.99 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 5.72 % | 5.59 % | 7.52 % | 7.53 % | 7.32 % |
| DIIs | 11.11 % | 10.43 % | 11.22 % | 11.78 % | 12.78 % | 11.92 % | 12.94 % | 13.69 % | 13.60 % | 13.23 % | 13.09 % | 12.79 % | 12.63 % | 12.64 % | 10.65 % | 10.65 % | 11.01 % |
| Government | 0.19 % | 0.07 % | 0.07 % | 0.07 % | 0.08 % | 0.08 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 6.16 % | 7.31 % | 7.38 % | 7.40 % | 7.81 % | 8.02 % | 7.60 % | 7.04 % | 6.42 % | 5.97 % | 5.67 % | 5.60 % | 5.29 % | 5.37 % | 5.48 % | 5.47 % | 5.41 % |
| Others | 7.66 % | 7.32 % | 6.44 % | 5.87 % | 4.46 % | 5.11 % | 4.48 % | 4.29 % | 5.00 % | 5.82 % | 6.26 % | 6.63 % | 1.38 % | 1.43 % | 1.37 % | 1.36 % | 1.28 % |
| No of Share Holders | 0 | 2,23,384 | 3,31,155 | 3,51,595 | 3,70,931 | 4,08,017 | 4,55,624 | 4,08,231 | 3,70,396 | 3,11,764 | 2,97,953 | 3,06,495 | 2,94,324 | 3,36,309 | 3,70,863 | 3,65,356 | 3,71,619 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 3.2 | 3.5 | 3.5 | 3.5 | 3.5 | 2.5 | 6 | 3 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.85 | 1.01 | 1.31 | 0.79 | 1 | 0.51 | 0.6 | 0.34 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 12 Aug 2025 |  Annual General Meeting | NA | 12 Aug 2025 | 911.40 | 908.00 |
| 20 May 2025 |  Quarterly Result Announcement | NA | 20 May 2025 | 873.70 | 911.40 |
| 05 Feb 2025 | Quarterly Result Announcement | NA | 05 Feb 2025 | 995.50 | 974.00 |
| 12 Nov 2024 | Quarterly Result Announcement | NA | 12 Nov 2024 | 1,002.20 | 968.55 |
| 09 Aug 2024 | Annual General Meeting | NA | 09 Aug 2024 | 1,009.00 | 1,279.40 |
| 26 Jul 2024 |  Dividend | ₹ 3.00 /share | 26 Jul 2024 | 1,009.00 | 1,205.80 |
| 28 Jul 2023 | Dividend | ₹ 6.00 /share | 28 Jul 2023 | 518.80 | 649.50 |
| 29 Jul 2022 | Dividend | ₹ 2.50 /share | 28 Jul 2022 | 338.75 | 349.60 |
| 30 Jul 2021 | Dividend | ₹ 3.50 /share | 28 Jul 2021 | 628.10 | 571.90 |
Announcements
Announcement under Regulation 30 (LODR)-Press Release / Media Release
2 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome4 days ago
4 days agoChange In Authority To Determine Materiality Of An Event4 days ago
4 days agoCompliances-Reg.24(A)-Annual Secretarial Compliance5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Investor Presentation5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Change in Management5 days ago
5 days agoRecord Date For Dividend Is July 25 20255 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Change in Management5 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Change in Directorate5 days ago
5 days agoCorporate Action-Board approves Dividend5 days ago
5 days agoAudited Financial Results For The Quarter And Year Ended March 31 20255 days ago
5 days agoBoard Meeting Outcome for Audited Financial Results For The Quarter And Year Ended March 31 20255 days ago
5 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication9 days ago
9 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 13, 2025
May 13, 2025Board Meeting Intimation for Approval Of Audited Financial Results For The Quarter / Year Ended On March 31 2025.May 09, 2025
May 09, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 08, 2025
May 08, 2025Announcement under Regulation 30 (LODR)-Change in ManagementApr 30, 2025
Apr 30, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 30, 2025
Apr 30, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 26, 2025
Apr 26, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 25, 2025
Apr 25, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionApr 25, 2025
Apr 25, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 17, 2025
Apr 17, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Apr 17, 2025
Apr 17, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 17, 2025
Apr 17, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 16, 2025
Apr 16, 2025Rumour verification - Regulation 30(11)Apr 16, 2025
Apr 16, 2025Clarification/Confirmation On News Item Appearing In "Www.Cnbctv18.Com"Apr 16, 2025
Apr 16, 2025Clarification sought from Zydus Lifesciences LtdApr 16, 2025
Apr 16, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 11, 2025
Apr 11, 2025Incorporation Of A Wholly Owned Subsidiary In FranceApr 11, 2025
Apr 11, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 09, 2025
Apr 09, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionMar 28, 2025
Mar 28, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 28, 2025
Mar 28, 2025Closure of Trading WindowMar 25, 2025
Mar 25, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 18, 2025
Mar 18, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 16, 2025
Mar 16, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 14, 2025
Mar 14, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 13, 2025
Mar 13, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 12, 2025
Mar 12, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 12, 2025
Mar 12, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMar 11, 2025
Mar 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 11, 2025
Mar 11, 2025Announcement under Regulation 30 (LODR)-AcquisitionMar 11, 2025
Mar 11, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 10, 2025
Mar 10, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 08, 2025
Mar 08, 2025Revised ESG ScoreMar 05, 2025
Mar 05, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 05, 2025
Mar 05, 2025Technical Indicators
RSI(14)
Neutral 56.78
ATR(14)
Less Volatile 23.56
STOCH(9,6)
Neutral 68.52
STOCH RSI(14)
Neutral 54.14
MACD(12,26)
Bullish 1.82
ADX(14)
Weak Trend 8.69
UO(9)
Bearish 57.16
ROC(12)
Uptrend And Accelerating 2.53
WillR(14)
Overbought -18.69
About Zydus Life Science
Zydus Lifesciences Limited is an Indian global life sciences company that discovers, develops, manufactures, and markets healthcare therapies. Its product portfolio includes active pharmaceutical ingredients, human formulations, animal health products, and wellness products. The company operates in pharmaceuticals, covering human and veterinary formulations, bulk drugs, diagnostics, herbal products, skin care, and over-the-counter products. Zydus has a global presence, marketing products in the United States, India, Europe, and emerging markets. Key products include Lipaglyn, Bilypsa, Ujvira, Exemptia, Vivitra, and Bryxta, covering areas such as oncology, autoimmune diseases, nephrology, and infectious illnesses. The company has manufacturing facilities in various Indian states and has made several strategic acquisitions and partnerships to expand its product range and market presence.
Listing Date
27 Apr, 2000(25 Years,
-2 days)
Website
Chairperson NamePankaj R Patel
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
